In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Aura Biosciences Inc (AURA – Research Report), with a price target of $21.00. The company’s shares opened today at $11.92.
Wolleben covers the Healthcare sector, focusing on stocks such as Altimmune, Intercept Pharma, and Madrigal Pharmaceuticals. According to TipRanks, Wolleben has an average return of 1.6% and a 37.18% success rate on recommended stocks.
Aura Biosciences Inc has an analyst consensus of Strong Buy, with a price target consensus of $28.00, a 134.90% upside from current levels. In a report released on July 27, Scotiabank also initiated coverage with a Buy rating on the stock with a $23.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $24.83 and a one-year low of $8.13. Currently, Aura Biosciences Inc has an average volume of 75.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aura Biosciences Inc is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity.
Read More on AURA:
